MannKind Announces $50 Million Private Placement
Rhea-AI Summary
MannKind (Nasdaq: MNKD) has entered into a securities purchase agreement for a private placement to certain institutional investors, led by Frazier Life Sciences, with expected gross proceeds of approximately $50 million. Closing is expected on or about July 24, 2026, subject to customary conditions.
According to MannKind, the company will sell 10,440,838 common shares and pre-funded warrants for up to 2,412,632 additional shares at $3.89 per share and $3.88 per pre-funded warrant. The pre-funded warrants have a $0.01 exercise price, are exercisable after issuance subject to beneficial ownership limits, and remain outstanding until fully exercised. MannKind plans to use net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment linked to FDA approval of Furoscix ReadyFlow™. The securities are unregistered and issued under Section 4(a)(2), and MannKind has agreed to file a resale registration statement with the SEC.
Positive
- Private placement gross proceeds expected at approximately $50 million
- Use of proceeds includes funding $45 million Furoscix ReadyFlow CVR payment
- Common share pricing set at $3.89 per share in the financing
- Pre-funded warrants structured with a $0.01 exercise price and no expiry until full exercise
Negative
- Potential dilution from 10,440,838 new shares plus 2,412,632 warrant shares
- Unregistered securities initially restricted until resale registration becomes effective
- $45 million CVR obligation requires significant cash outlay funded from proceeds
News Explained
The agreed financing would add shares and potential warrant shares, creating conditional dilution while providing approximately $50 million before costs.
MannKind has entered an agreement for approximately
If it closes, the issuance of common shares and potential warrant shares increases the share count and can reduce existing holders’ percentage ownership. The pre-funded warrants are sold at nearly the full share price with a nominal exercise price and convert into shares when exercised.
Because closing is pending, the ownership effect is conditional rather than completed, and the warrant-related portion depends on exercise. On the supplied quarterly operating-cash-use basis, the gross financing equals
Sources and calculations
- MannKind Announces $50 Million Private Placement (2026-07-24)
- Dilution (undated)
- Pre-funded warrant (undated)
- MannKind first-quarter fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $50,000,000 / ($5,365,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $52,834,000 / ($5,365,000 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | clinical trial grant | Positive | +1.0% | Breakthrough T1D grant supported the ongoing INHALE-1ST pediatric trial. |
| Jun 05 | clinical data presentation | Positive | +0.9% | ADA studies reported pediatric, pregnancy, delivery-system, and heart-failure findings. |
| Jun 03 | clinical trial milestones | Positive | -2.0% | INFLO-1 randomization completed and INFLO-2 enrolled its first patient. |
| May 29 | approval conference call | Positive | +3.6% | Conference call addressed Afrezza's pediatric FDA approval. |
| May 29 | FDA approval | Positive | +3.6% | FDA approved Afrezza for children and adolescents aged six and older. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of the five recent news events were followed by positive 24-hour reactions, while the June 3 clinical-trial milestone diverged with a negative reaction.
Key Terms
private placement financial
securities purchase agreement financial
pre-funded warrants financial
section 4(a)(2) regulatory
registration statement regulatory
contingent value rights financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placement financing are expected to be approximately
The private placement was led by Frazier Life Sciences, a longstanding biotech investment firm.
MannKind intends to use the net proceeds for general corporate purposes, including funding the
Pursuant to the terms of the securities purchase agreement, MannKind is selling an aggregate of 10,440,838 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,412,632 shares of its common stock, at a purchase price of
The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and are being issued and sold in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. MannKind has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the pre-funded warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Forward Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the satisfaction of closing conditions for a private placement and the payment to holders of contingent value rights associated with a regulatory milestone. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that MannKind’s products may only achieve a limited degree of commercial success, and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
FUROSCIX READYFLOW and MANNKIND are trademarks of MannKind Corporation.
MannKind Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com